$MYOV News

Last published 2y ago

2y agoMYOVApproval of Myfembree, Nda #214846 (Efficacy)FDA Approved DrugsApproval Date: 05/07/2024; Drug Name: Myfembree, Nda #214846; Active Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX; Company: Myovant Sciences; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 214846
3y agoPFE MYOVCoronary CT Angiography Scan in Prostate Cancer - NCT05879913ClinicalTrials.govProportion of Atherosclerosis in CCTA Arm, Proportion of Subjects Eligible for Treatment Based on Automated Plaque Assessment from CCTA, Reduction in atherosclerotic cardiovascular disease (ASCVD) risk score
3y agoMYOVA Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis - NCT05862272ClinicalTrials.govPercent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in women with uterine fibroids., Percent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in women with endometriosis., Percent change from baseline in BMD at Month 48 on-treatment at total hip and femoral neck in women with uterine fibroids., (and 14 more...)
3y agoMYOVMYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy - NCT05739136ClinicalTrials.govMajor Congenital Malformation (MCM), Spontaneous abortion (SAB), Stillbirth, (and 2 more...)
3y agoMYOVRelugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring - NCT05739123ClinicalTrials.govMajor Congenital Malformation (MCM), Minor congenital malformations, Spontaneous abortion (SAB), (and 6 more...)
3y agoMYOVMyovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022GlobeNewswireThird fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential
3y agoMYOVMYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant SciencesPR NewswireNEW YORK, Dec. 16, 2022 /PRNewswire/ -- Shareholder rights law firm Julie & Holleman is investigating the proposed acquisition of Myovant Sciences (NYSE:MYOV) by affiliates of its controlling shareholder, Sumitovant
3y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines,
3y agoMYOVMyovant Sciences Appoints Ann Tomlin as Senior Vice President of Human ResourcesGlobeNewswireBASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be
3y agoMYOVUrovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel SeasonBusiness WireUrovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB) For Patients With OAB, Traveling or Enjoying a Night Out Can Be a
4y agoMYOVRandomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate - NCT05605964ClinicalTrials.govTime to Major Adverse Cardiovascular Event (MACE), Time Course of Events Related to MACE, Incidence of Safety Outcomes
4y agoMYOVUrovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed TabletBusiness WireA new peer-reviewed journal paper suggests that crushing GEMTESA (vibegron) 75-mg and taking it with applesauce may be an appropriate option for people with overactive bladder (OAB) and concommitant swallowing
4y agoMYOVMyovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022GlobeNewswireOn October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a
4y agoMYOVMyovant Sciences Cancels Second Quarter Earnings Conference CallGlobeNewswireBASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) ("Myovant") today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had
4y agoTSLA BABA LVS WYNN+19Stocks making the biggest moves midday: Avis, Pinduoduo, Starbucks, Alibaba and moreCNBCThese are the stocks posting the largest moves midday.
4y agoMYOVSumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive AgreementGlobeNewswireSumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate Cancer Agreement
4y agoMYOVSumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive AgreementPR NewswireSumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women's Health and Prostate Cancer Agreement
4y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines,
4y agoMYOVMyovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.GlobeNewswireBASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal
4y agoOXY COP FANG HAL+19Stocks making the biggest moves midday: Peloton, Tesla, Viasat, Wells Fargo, Box and moreCNBCThese are the stocks posting the largest moves midday.
4y agoCS TSLA VSAT LHX+6Stocks making the biggest moves in the premarket: Credit Suisse, Tesla, Myovant Sciences and moreCNBCThe stocks making the biggest moves in premarket trading include Credit Suisse, Tesla, Myovant Sciences, and more.
4y agoMYOVMyovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining SharesGlobeNewswireBASEL, Switzerland, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences Ltd. (NYSE:MYOV) (the "Company") confirmed today that it has received a preliminary, non-binding proposal (the "Proposal") from Sumitovant Biopharma Ltd. ("Sumitovant") and Sumitomo
4y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, t
4y agoMYOVMyovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be InformedGlobeNewswireBASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through authentic conversations, along with the sponsorship
4y agoMYOVUrovant Sciences® Receives "Best in Category" Award for Abstract Highlighting Investigational Novel Gene Therapy, URO-902, Presented at 2022 International Continence Society ConferenceBusiness WireInterim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence Society (ICS) recognition for "Best in Category Prize: O
4y agoMYOVUrovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)Business WireUrovant Sciences, Inc. receives Fortune and Great Place to Work Best Workplaces in BioPharma (2022) recognition. Follows Urovant's Best Place to Work recognition by the Orange County Business Journal for the second year in a row, along with becomi
4y agoMYOVMyovant Sciences to Participate at Upcoming Investor ConferencesGlobeNewswireBASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, to
4y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, to
4y agoMYOV PFEMyovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With EndometriosisGlobeNewswireData from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment M
4y agoMYOVMyovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022GlobeNewswireFirst fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growt
4y agoMYOVMyovant Sciences Ltd. (MYOV) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsMYOV earnings call for the period ending June 30, 2022.
4y agoMYOVThe OPTYX Prostate Cancer Registry - NCT05467176ClinicalTrials.govDemographics, Selective Safety Data, Health-Related Quality-of-Life Indicators, (and 5 more...)
4y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, July 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, to
4y agoMYOVThe Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New SurveyBusiness WireSurvey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC) settings, according to this peer-reviewed journal pap
4y agoMYOVMyovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022GlobeNewswireBASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022. The w
4y agoMYOVUrovant Sciences® Named One of 2022 "Best Places to Work" in Orange CountyBusiness WireThis is Urovant's second year in a row to earn this recognition by Orange County Business Journal Urovant has also received a 2022 global Great Place to Work™ certification. The culmination of these two awards reflects the company's people f
4y agoMYOVUrovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and SwitzerlandBusiness WirePierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences GmbH to receive compensation of up to USD $75 milli
4y agoMYOVEnzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric ConditionGlobeNewswireCAMBRIDGE, Mass. and BASEL, Switzerland, June 27, 2022 (GLOBE NEWSWIRE) -- Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today it is among the National Organization for Rare Disor
4y agoMYOV PFEMyovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated PainGlobeNewswireBASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination the
4y agoMYOVMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08GlobeNewswireBASEL, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, to
4y agoBTTX EXEL MYOVBetter Therapeutics Appoints Frank Karbe as Chief Executive OfficerBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the
4y agoMYOVMyovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewswireBASEL, Switzerland, June 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, tod
4y agoMYOV PFEMyovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®GlobeNewswireBASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV) and Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA
4y agoMYOVSpirovant Launches State-of-the-Art Laboratory and HeadquartersPR NewswireThe facilities are located in the center of Philadelphia's thriving life sciences corridor PHILADELPHIA, May 16, 2022 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis (
4y agoMYOVUrovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingBusiness WireNew analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium presentations PD38-11 and PD38-12: In a subgroup
4y agoMYOVUrovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association MeetingBusiness WireInterim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to
4y agoMYOV PHAT URGNPhathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business UpdatesGlobeNewswireU.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 mi
4y agoMYOVMyovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022GlobeNewswireFiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 million European Commission approval of ORGOVYX® as t
4y agoMYOVMyovant Sciences Ltd. (MYOV) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsMYOV earnings call for the period ending March 31, 2022.
4y agoMYOVMyovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in EuropeGlobeNewswireMyovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million Myovant also eligible to receive tiered royalties from the high-teens to mid-twenties on net